This study also showed that the Sinopharm/BBIBP-CorV vaccinees who received the booster had high levels of ACE2 blocking antibodies (surrogate marker for neutralizing antibodies), although the positivity rates were lower than following natural infection. Here, ACE2 is linked to infection.